250 related articles for article (PubMed ID: 8821628)
1. CD3 and CD2 ligation alters CD49d epitope expression.
Lin J; Qin L; Chavin KD; Ding Y; Punch JD; Yang Q; Burkly LC; Bromberg JS
Pathobiology; 1995; 63(3):119-32. PubMed ID: 8821628
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CD3.
Lin J; Chavin KD; Qin L; Ding Y; Bromberg JS
Cell Immunol; 1996 Feb; 167(2):249-58. PubMed ID: 8603434
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2.
Lin J; Yon RW; Chavin KD; Qin L; Woodward J; Ding Y; Yagita H; Bromberg JS
Transplantation; 1995 Apr; 59(8):1162-71. PubMed ID: 7537394
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
[TBL] [Abstract][Full Text] [Related]
5. Increased cAMP and cAMP-dependent protein kinase activity mediate anti-CD2 induced suppression of anti-CD3-driven interleukin-2 production and CD25 expression.
Lin J; Gettys TW; Qin L; Chavin KD; Yang Q; Ding Y; Punch JD; Bromberg JS
Pathobiology; 1995; 63(4):175-87. PubMed ID: 8866788
[TBL] [Abstract][Full Text] [Related]
6. CD2 and CD3 receptor-mediated tolerance: constraints on T cell activation.
Punch JD; Lin J; Bluestone J; Bromberg JS
Transplantation; 1999 Mar; 67(5):741-8. PubMed ID: 10096532
[TBL] [Abstract][Full Text] [Related]
7. CD2 is a dominant target for allogeneic responses.
Bai Y; Fu S; Honig S; Wang Y; Qin L; Chen D; Bromberg JS
Am J Transplant; 2002 Aug; 2(7):618-26. PubMed ID: 12201362
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against human T cell adhesion molecules--modulation of immune function in nonhuman primates.
Berlin PJ; Bacher JD; Sharrow SO; Gonzalez C; Gress RE
Transplantation; 1992 Apr; 53(4):840-9. PubMed ID: 1348883
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression.
Bergese SD; Pelletier RP; Ohye RG; Vallera DA; Orosz CG
Transplantation; 1994 Mar; 57(5):711-7. PubMed ID: 7511256
[TBL] [Abstract][Full Text] [Related]
10. Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-negative large granular lymphocytes.
Timonen T; Gahmberg CG; Patarroyo M
Int J Cancer; 1990 Dec; 46(6):1035-40. PubMed ID: 1979068
[TBL] [Abstract][Full Text] [Related]
11. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
[TBL] [Abstract][Full Text] [Related]
12. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model.
Chavin KD; Qin L; Lin J; Yagita H; Bromberg JS
J Immunol; 1993 Dec; 151(12):7249-59. PubMed ID: 7903105
[TBL] [Abstract][Full Text] [Related]
13. A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants.
Yang SY; Chouaib S; Dupont B
J Immunol; 1986 Aug; 137(4):1097-100. PubMed ID: 2426350
[TBL] [Abstract][Full Text] [Related]
14. Activation of cord T lymphocytes. III. Role of LFA-1/ICAM-1 and CD2/LFA-3 adhesion molecules in CD3-induced proliferative response.
Gerli R; Agea E; Muscat C; Tognellini R; Fiorucci G; Spinozzi F; Cernetti C; Bertotto A
Cell Immunol; 1993 Apr; 148(1):32-47. PubMed ID: 7684326
[TBL] [Abstract][Full Text] [Related]
15. Expression of a novel integrin beta 1 chain epitope and anti-beta 1 antibody-mediated enhancement of fibronectin binding are dependent on the stage of T cell differentiation.
Wadsworth SA; Chang AC; Hong MJ; Halvorson MJ; Otto S; Coligan JE
J Immunol; 1995 Mar; 154(5):2125-33. PubMed ID: 7532661
[TBL] [Abstract][Full Text] [Related]
16. Cultured human thymocytes lacking CD2 and CD11a/CD18 antigens are functional and adhere to endothelial cells via CD56 or CDw49d molecules.
Poggi A; Zocchi MR
Cell Immunol; 1992 Apr; 140(2):319-30. PubMed ID: 1371947
[TBL] [Abstract][Full Text] [Related]
17. Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes.
Pulido R; Elices MJ; Campanero MR; Osborn L; Schiffer S; García-Pardo A; Lobb R; Hemler ME; Sánchez-Madrid F
J Biol Chem; 1991 Jun; 266(16):10241-5. PubMed ID: 1709929
[TBL] [Abstract][Full Text] [Related]
18. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production.
Chavin KD; Qin L; Lin J; Woodward JE; Baliga P; Bromberg JS
Ann Surg; 1993 Oct; 218(4):492-501; discussion 501-3. PubMed ID: 8215640
[TBL] [Abstract][Full Text] [Related]
19. Treatment of cardiac allografts with established leukocyte infiltration by modulation of alpha4 (CD49d) and leukocyte function-associated antigen-1 (CD11a/CD18) integrin function.
Chan BM; Zheng H; Wang H; Uniyal S; Garcia B; Wang J; Zhong R
Transplantation; 1998 Aug; 66(3):277-83. PubMed ID: 9721793
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival.
Qin L; Chavin KD; Lin J; Yagita H; Bromberg JS
J Exp Med; 1994 Jan; 179(1):341-6. PubMed ID: 7903681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
